The biopharma Terns Pharmaceuticals (NSDQ:TERN) has appointed Dr. Ann E. Taylor to its board of directors.
Taylor, who served as AstraZeneca‘s chief medical officer from April 2019 to August 2021, has more than 35 years of experience in drug development. Other notable companies she has worked for include Pfizer, Novartis and AstraZeneca subsidiary MedImmune.
Dr. Taylor currently serves on the board of directors of Unlearn.AI, a company focused on accelerating clinical trials with artificial intelligence.
She has authored and co-authored 48 peer-reviewed papers, 27 book chapters and reviews and served on the editorial board of the Journal of Clinical Endocrinology and Metabolism.
Foster City, California–based Terns is focused on developing therapies for nonalcoholic steatohepatitis (NASH), which involves liver inflammation and potentially scarring (cirrhosis). “NASH remains an area of significant unmet need and I believe Terns’ approach, which seeks to combine best-in-class molecules with clinically validated mechanisms in NASH, will play a significant part in the treatment of NASH patients,” said Taylor, in a statement.
Earlier this month, Terns announced it had completed patient enrollment of Part 1 of its AVIATION Trial, a Phase 1b study investigating TERN-201 in NASH. The drug is a highly selective inhibitor of vascular adhesion protein-1 (VAP-1).
Filed Under: Hepatology